Drug · DIN 00285528
TRAVASOL E
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since October 19, 2017; first marketed December 31, 1974.
- Drug Identification Number (DIN)
- 00285528
- Company (DIN owner)
- Baxter CorporationMississauga, Ontario, Canada
- Schedule
- Ethical
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Combinations B05BA10
- Class
- Human
- Record last updated
- June 23, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LEUCINE | 620 MG | 100 ML |
| PHENYLALANINE | 620 MG | 100 ML |
| METHIONINE | 580 MG | 100 ML |
| L-LYSINE (L-LYSINE HYDROCHLORIDE) | 580 MG | 100 ML |
| ISOLEUCINE | 480 MG | 100 ML |
| VALINE | 460 MG | 100 ML |
| HISTIDINE | 440 MG | 100 ML |
| THREONINE | 420 MG | 100 ML |
| TRYPTOPHAN | 180 MG | 100 ML |
| ALANINE | 2.08 G | 100 ML |
| GLYCINE | 2.08 G | 100 ML |
| ARGININE | 1.04 G | 100 ML |
| PROLINE | 420 MG | 100 ML |
| TYROSINE | 40 MG | 100 ML |
| SODIUM ACETATE | 680 MG | 100 ML |
| POTASSIUM PHOSPHATE DIBASIC | 522 MG | 100 ML |
| SODIUM CHLORIDE | 117 MG | 100 ML |
| MAGNESIUM CHLORIDE | 102 MG | 100 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 7, 2013: NOC 14805Supplement to a New Drug Submission (SNDS) · Product name change